Trefoil Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $12M

  • Investors
  • 12

Trefoil Therapeutics General Information

Description

Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is focused on leveraging its engineered fibroblast growth factor-1 protein technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases and help regenerate the endothelial cell layer and eliminate the symptoms associated with this condition that leads to the loss of vision, enabling ophthalmologists to treat patients with severe corneal endothelial diseases and epithelial disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 6330 Nancy Ridge Drive
  • Suite 103
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Trefoil Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A1) 22-Mar-2022 $12M 000.00 0000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 05-Aug-2019 0000 000.00 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series 1) 05-Jan-2017 00.00 00.00 00.00 Completed Startup
2. Grant 20-Oct-2015 Completed Startup
1. Accelerator/Incubator 01-Jan-2013 Completed Startup
To view Trefoil Therapeutics’s complete valuation and funding history, request access »

Trefoil Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series 1 18,551,984 $0.000100 7% $0.28 $0.28 1x $0.28 10.67%
To view Trefoil Therapeutics’s complete cap table history, request access »

Trefoil Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is
Biotechnology
San Diego, CA
10 As of 2024
000.00
0000 0000-00-00
00000000000 000.00

00000

piscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000 0000-00-00
00000000000 00000

00000

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
0000 000000000
New York, NY
00 As of 0000
000.00
000000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Trefoil Therapeutics Competitors (84)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Casma Therapeutics Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
Ember Therapeutics Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Aurora Biopharma Angel-Backed New York, NY 00000 0000000000 00000
Immusoft Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
You’re viewing 5 of 84 competitors. Get the full list »

Trefoil Therapeutics Patents

Trefoil Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4172351-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 26-Jun-2020 0000000000
US-20240024421-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 26-Jun-2020 00000000000
AU-2018261021-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 05-May-2017 000000000
CA-3062473-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 05-May-2017 000000000
EP-3619324-A4 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 05-May-2017 C07K14/50 0
To view Trefoil Therapeutics’s complete patent history, request access »

Trefoil Therapeutics Executive Team (6)

Name Title Board Seat
David Eveleth Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Schalon Newton Chief Business Officer
Michael Blaber Ph.D Co-Founder & Scientific Advisory Board Member
Kenneth Thomas Ph.D Co-Founder, Scientific Advisory Member & Consultant
Ralph Bradshaw Ph.D Co-Founder & Chairman of Scientific Advisory Board
You’re viewing 5 of 6 executive team members. Get the full list »

Trefoil Therapeutics Board Members (8)

Name Representing Role Since
Benjamin McGraw III Self Executive Chair of the Board 000 0000
Christy Shaffer Ph.D Hatteras Venture Partners Board Member 000 0000
David Eveleth Ph.D Trefoil Therapeutics Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Derek Yoon AJU IB Investment Board Member 000 0000
Liam Ratcliffe Ph.D Access Biotechnology Board Observer 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Trefoil Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trefoil Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Solasta Ventures Venture Capital Minority 000 0000 000000 0
Access Biotechnology Corporate Venture Capital Minority 000 0000 000000 0
Bios Partners Venture Capital Minority 000 0000 000000 0
FemHealth Ventures Venture Capital Minority 000 0000 000000 0
AJU IB Investment Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Trefoil Therapeutics FAQs

  • When was Trefoil Therapeutics founded?

    Trefoil Therapeutics was founded in 2013.

  • Who is the founder of Trefoil Therapeutics?

    David Eveleth Ph.D, Michael Blaber Ph.D, Kenneth Thomas Ph.D, and Ralph Bradshaw Ph.D are the founders of Trefoil Therapeutics.

  • Who is the CEO of Trefoil Therapeutics?

    David Eveleth Ph.D is the CEO of Trefoil Therapeutics.

  • Where is Trefoil Therapeutics headquartered?

    Trefoil Therapeutics is headquartered in San Diego, CA.

  • What is the size of Trefoil Therapeutics?

    Trefoil Therapeutics has 10 total employees.

  • What industry is Trefoil Therapeutics in?

    Trefoil Therapeutics’s primary industry is Biotechnology.

  • Is Trefoil Therapeutics a private or public company?

    Trefoil Therapeutics is a Private company.

  • What is the current valuation of Trefoil Therapeutics?

    The current valuation of Trefoil Therapeutics is 0000.

  • What is Trefoil Therapeutics’s current revenue?

    The current revenue for Trefoil Therapeutics is 000000.

  • How much funding has Trefoil Therapeutics raised over time?

    Trefoil Therapeutics has raised $45.2M.

  • Who are Trefoil Therapeutics’s investors?

    Solasta Ventures, Access Biotechnology, Bios Partners, FemHealth Ventures, and AJU IB Investment are 5 of 12 investors who have invested in Trefoil Therapeutics.

  • Who are Trefoil Therapeutics’s competitors?

    Casma Therapeutics, Ember Therapeutics, NexImmune, Aurora Biopharma, and Immusoft are some of the 84 competitors of Trefoil Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »